Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03825796 · ClinicalTrials.gov registry record · Phase 2
CPX-351 Plus Enasidenib for Relapsed AML
A Phase 2 study of Recurrent Acute Myeloid Leukemia, sponsored by Jonsson Comprehensive Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
- 3
- Study locations
NCT03825796 is a Phase 2 study of Recurrent Acute Myeloid Leukemia that is active but no longer recruiting, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 2 participants, below the 58-participant average among 57 other Recurrent Acute Myeloid Leukemia trials with a reported enrollment target (97% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT03825796, a Phase 2 study of Recurrent Acute Myeloid Leukemia, is active but no longer recruiting, sponsored by Jonsson Comprehensive Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
- 3
- Study locations
Study Summary
This trial evaluates how well CPX-351 and enasidenib work in treating patients with acute myeloid leukemia characterized by IHD2 mutation. Drugs used in chemotherapy, such as CPX-351, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Enasidenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving CPX-351 and enasidenib may work better in treating patients with acute myeloid leukemia, compared to giving only one of these therapies alone.
Conditions Studied
Interventions
- DRUG Liposome-encapsulated Daunorubicin-Cytarabine
- DRUG Enasidenib Mesylate
Study Locations (3)
California
- UCLA / Jonsson Comprehensive Cancer Center - Los Angeles
- University of California Davis Comprehensive Cancer Center - Sacramento
- University of California San Diego - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2019-04-12 |
| Est. Completion | 2024-09-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03825796
The ClinicalTrials.gov registry entry for NCT03825796 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 58-participant average among 57 other Recurrent Acute Myeloid Leukemia trials with a reported enrollment target (97% lower). The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Recurrent Acute Myeloid Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Liposome-encapsulated Daunorubicin-Cytarabine is the first listed.
NCT03825796 reports 3 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03825796 about?
NCT03825796 is a clinical study titled "CPX-351 Plus Enasidenib for Relapsed AML". This trial evaluates how well CPX-351 and enasidenib work in treating patients with acute myeloid leukemia characterized by IHD2 mutation. Drugs used in chemotherapy, such as CPX-351, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividi...
What is the current status of trial NCT03825796?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2019-04-12. Estimated completion is 2024-09-01.
What conditions does trial NCT03825796 study?
This clinical trial studies the following conditions: Recurrent Acute Myeloid Leukemia.
What interventions are being tested in trial NCT03825796?
The interventions under investigation include: Liposome-encapsulated Daunorubicin-Cytarabine (DRUG), Enasidenib Mesylate (DRUG).
Who is sponsoring clinical trial NCT03825796?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03825796 being conducted?
This trial has 3 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
RECRUITING · Phase 2
-
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
RECRUITING · Phase 2
-
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
RECRUITING · Phase 2
-
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
RECRUITING · Phase 2
-
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
RECRUITING · Phase 2
-
Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.